Objective: The aim of this study was to collect comparable and reliable data about consumption of drugs for treatment of diabetes mellitus in Slovakia during the period 1996 – 2006. Methods: Data of wholesalers (following ATC/DDD), who are legally obliged provide this information to the Slovak Institute for Drug Control, was used for the analysis. The results were expressed in the numbers of the packages, finance units (€) and defined daily doses per 1000 inhabitants per day (DID). Results: The collected data shows a moderate increases in the antidiabetic's consumption from 1996 to 2006 in term of DID (in 1996 (27.03), in 2001 (32.62) and in 2006 (37.90). A slight increase in A10AB group (Insulins and analogues, fast-acting) in 1996 (1.88), in 2001 (2.79) and in 2006 (4.64), a slight decrease in A10AC group (Insulins and analogues, intermediate-acting) in 1996 (4.25), in 2001 (3.74) and in 2006 (3.35), a moderate increase in A10AD (Insulins and analogues, intermediate-acting combin.) in 1996 (0.51), in 2001 (2.36) and in 2006 (3.25), a steady increase in A10AE (Insulins and analogues, long-acting) in 2001 (0.03) and in 2006 (0.89), a dramatic increase in A10BA (Biguanides) in 1996 (4.45), in 2001 (5.75) and in 2006 (9.46), relatively stable consumption in A10BB (Sulfonamides, urea derivatives) in 1996 (15.33), in 2001 (17.19) and in 2006 (14.76) and a moderate increase in A10BD (Biguanides and sulfonamides in combination) in 2001 (0.07) and in 2006 (1.41) in term of DID can be seen from this analysis. Financial expenditures for antidiabetics were (in 1996 (€9,772,000), in 2001 (€18,169,000) and in 2006 (€26,541,000). Conclusion: Inseparable components of the Slovak drug policy must be viewed realistically with regard to the antidiabetics' consumption. Adherence to principles of diabetes mellitus treatment's guidelines lead to fundamental short and long term financial savings within health care systems.